122 related articles for article (PubMed ID: 38691509)
41. Public Health and Pharmacy Partnerships in Opioid Harm Reduction: Responding to Community Needs.
Medina S; Tomaszewski R; Chhen S; Hanson A; Mueller A; Palombi LC
Prog Community Health Partnersh; 2021; 15(1):37-46. PubMed ID: 33775959
[TBL] [Abstract][Full Text] [Related]
42. Impact of a statewide community pharmacy approach to opioid harm reduction.
Sexton SM; Marciniak MW; Gatton O; Shelton P
J Am Pharm Assoc (2003); 2023; 63(1):389-395.e1. PubMed ID: 36369073
[TBL] [Abstract][Full Text] [Related]
43. Naloxone Deserts in NJ Cities: Sociodemographic Factors Which May Impact Retail Pharmacy Naloxone Availability.
Lozo KW; Nelson LS; Ramdin C; Calello DP
J Med Toxicol; 2019 Apr; 15(2):108-111. PubMed ID: 30805884
[TBL] [Abstract][Full Text] [Related]
44. Patient, family members and community pharmacists' views of a proposed overdose prevention intervention delivered in community pharmacies for patients prescribed high-strength opioids for chronic non-cancer pain: An explorative intervention development study.
Mercer F; Parkes T; Foster R; Steven D; McAuley A; Baldacchino A; Steele W; Schofield J; Matheson C
Drug Alcohol Rev; 2023 Mar; 42(3):517-526. PubMed ID: 36165733
[TBL] [Abstract][Full Text] [Related]
45. The evaluation of mandatory alerts on long-acting opioid prescriptions and the use of a community pharmacy naloxone protocol.
Coffman R; Johnson A; Frede S; Pleiman M; Johnson K
J Am Pharm Assoc (2003); 2022; 62(4S):S35-S40.e1. PubMed ID: 34930681
[TBL] [Abstract][Full Text] [Related]
46. Addressing the opioid epidemic through community pharmacy engagement: Study protocol for a randomized controlled trial.
Gamble A; Mashburn T; Kennelty KA; Look KA; Westrick SC; Evon DM; Tudor G; Carpenter DM
Contemp Clin Trials; 2022 Oct; 121():106920. PubMed ID: 36096283
[TBL] [Abstract][Full Text] [Related]
47. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
[TBL] [Abstract][Full Text] [Related]
48. Pilot implementation of the PharmNet naloxone program in an independent pharmacy.
Eldridge LA; Meyerson BE; Agley J
J Am Pharm Assoc (2003); 2023; 63(1):374-382.e12. PubMed ID: 36209035
[TBL] [Abstract][Full Text] [Related]
49. Pharmacists' knowledge, support, and perceived roles associated with providing naloxone in the community.
Stewart B; Thomas RL; Tutag-Lehr V
Curr Pharm Teach Learn; 2018 Aug; 10(8):1013-1021. PubMed ID: 30314535
[TBL] [Abstract][Full Text] [Related]
50. Point-of-sale Naloxone: Novel Community-based Research to Identify Naloxone Availability.
Olives T; Willhite LA; Lee SC; Evans DK; Jensen A; Regelman HT; McGillis ES
West J Emerg Med; 2020 Aug; 21(5):1188-1194. PubMed ID: 32970574
[TBL] [Abstract][Full Text] [Related]
51. Implementation of academic detailing for pharmacists on opioid use disorder and harm reduction.
DiPaula BA; Cooke CE; Boyle CJ; Love RC
J Am Pharm Assoc (2003); 2022; 62(1):241-246. PubMed ID: 34690080
[TBL] [Abstract][Full Text] [Related]
52. Factors associated with how often community pharmacists offer and dispense naloxone.
Carpenter DM; Dhamanaskar AK; Gallegos KL; Shepherd G; Mosley SL; Roberts CA
Res Social Adm Pharm; 2019 Dec; 15(12):1415-1418. PubMed ID: 30007530
[TBL] [Abstract][Full Text] [Related]
53. Pharmacists' perceptions regarding feasibility, acceptability, and usefulness of student-delivered naloxone education services in community pharmacy: A mixed methods study in Alabama.
Hohmann L; Maxson R; McDowell L
J Am Pharm Assoc (2003); 2023; 63(6):1731-1742.e4. PubMed ID: 37619850
[TBL] [Abstract][Full Text] [Related]
54. Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose.
Skoy E; Eukel H; Werremeyer A; Strand M; Frenzel O; Steig J
J Am Pharm Assoc (2003); 2020; 60(1):117-121. PubMed ID: 31677933
[TBL] [Abstract][Full Text] [Related]
55. "I go out of my way to give them an extra smile now:" A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials.
Irwin AN; Gray M; Ventricelli D; Boggis JS; Bratberg J; Floyd AS; Silcox J; Hartung DM; Green TC
Res Social Adm Pharm; 2024 May; 20(5):512-519. PubMed ID: 38395644
[TBL] [Abstract][Full Text] [Related]
56. Comparing women pharmacy consumers' experiences with weight loss treatment in Victoria and Nottingham: a cross-sectional study.
Fakih S; Marriott JL; Boardman H; Anderson C; Hussainy SY
BMC Public Health; 2014 Jun; 14():662. PubMed ID: 24972611
[TBL] [Abstract][Full Text] [Related]
57. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.
Slocum S; Ozga JE; Joyce R; Walley AY; Pollini RA
BMC Public Health; 2022 Apr; 22(1):735. PubMed ID: 35418048
[TBL] [Abstract][Full Text] [Related]
58. Dispensing Naloxone Without a Prescription: Survey Evaluation of Ohio Pharmacists.
Thompson EL; Rao PSS; Hayes C; Purtill C
J Pharm Pract; 2019 Aug; 32(4):412-421. PubMed ID: 29478362
[TBL] [Abstract][Full Text] [Related]
59. Limited access to pharmacy-based naloxone in West Virginia: Results from a statewide purchase trial.
Pollini RA; Ozga JE; Joyce R; Xuan Z; Walley AY
Drug Alcohol Depend; 2022 Feb; 231():109259. PubMed ID: 34998246
[TBL] [Abstract][Full Text] [Related]
60. Impact of pharmacist counseling to enhance the accessibility of naloxone nasal spray to patients in a community pharmacy setting.
Napoli K; Grant M; Remines J; Nadpara P; Goode JR
J Am Pharm Assoc (2003); 2021; 61(4S):S127-S134. PubMed ID: 33441280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
